all about terminal illnesses
← All diseases Brain and nervous system

Multiple system atrophy (MSA)

Would you like to receive a message when there is new research about Multiple System Atrophy (MSA)? This is possible with an account. Create a free account or log in.

Last updated: 2026-08-09 · automatically checked, spot-checked

# Multiple System Atrophy

What is it

Multiple System Atrophy (MSA) is a rare, progressive disease of the nervous system. It is characterized by the accumulation of a protein called alpha-synuclein in nerve cells. This protein damages various parts of the brain that are important for movement, blood pressure, heart rate, and other vital functions.

The disease belongs to a group of diseases called "synucleinopathies" – in which this protein plays a central role. MSA distinguishes itself by the fact that multiple systems are affected simultaneously: movement, autonomic functions (such as blood pressure and fluid balance) and sometimes cognition.

MSA is incurable and progressive, meaning that symptoms worsen over time. It is a rare condition; worldwide, approximately 3 to 5 per 100,000 people receive this diagnosis.

Causes

The exact cause of MSA is unknown. It is known that alpha-synuclein accumulates in a specific way in certain brain areas, particularly in the cerebellum, the brainstem, and certain areas that regulate movement and autonomic functions. This leads to loss of nerve cells (neurons).

There is no strong hereditary component – MSA usually occurs sporadically, so not in families. Research into genetic risk factors, environmental factors, and cellular processes that may lead to MSA is ongoing. However, it is currently not clear what triggers this accumulation of alpha-synuclein.

How the disease progresses

MSA usually follows a rapidly progressive course, faster than related diseases such as Parkinson's disease. Many patients have a limited life expectancy on average from the time of diagnosis.

The disease is often classified according to which symptom appears first:
- **Parkinsonism-dominant (MSA-P)**: movement symptoms are prominent, with stiffness and slowness.
- **Cerebellar variant (MSA-C)**: coordination problems and loss of balance are prominent.

In both variants, autonomic symptoms will eventually appear – that is characteristic of MSA. The progression varies from person to person: some deteriorate faster, others more slowly.

MRI examination can sometimes show patterns of brain atrophy that help estimate the course, and new techniques such as iron measurement in brain tissue are being investigated.

Symptoms by phase

Early stage At the beginning, symptoms can be subtle and increase slowly. Many patients notice: - Stiffness, slowness, or unsteady movements - Mild dizziness, especially when standing up - Tremors or coordination problems - Possible sleep problems or REM sleep behavior (vivid dreams with movements)

Middle stage Symptoms become clearer and more troublesome: - **Movement**: more stiffness, lower voice, slower movements, balance problems - **Autonomic functions**: blood pressure drop when standing (orthostasis) with dizziness, heart rhythm disorders, fluid balance problems - **Swallowing**: difficulties eating or drinking; risk of aspiration (food in airways) - **Urinary symptoms**: urgency, incontinence, nighttime urination - **Sexual function**: erectile problems - **Breathing**: hoarseness, sometimes breathing problems

Late stage In the later stage: - Severe loss of mobility; many patients need a wheelchair - Significant swallowing difficulties; feeding via tube may be necessary - Autonomic symptoms may stabilize or worsen - Possible breathing problems with need for respiratory support - Possible cognitive changes, although this is less prominent than in other dementia disorders

What it means for daily life

MSA has major consequences for independence and quality of life, because it affects so many systems.

**Mobility and falling**: The combination of coordination disorders, muscle stiffness, and blood pressure drop makes falling very likely. Many patients need aids relatively quickly: first a cane or walker, later a wheelchair. This limits activities outside the home.

**Eating and drinking**: Swallowing difficulties can be serious and compromise nutrition. This sometimes requires adjustments to food consistency, eating more slowly, or eventually nutrition via a feeding tube. Malnutrition and weight loss are common and can affect prognosis.

**Speech**: Many patients develop a rougher, softer voice and difficulty speaking clearly – which makes communication harder.

**Autonomic symptoms**: Low blood pressure requires caution when standing up, increased fluid intake, sometimes compression clothing or medication. Urinary symptoms can be embarrassing and limit social activities.

**Sleep**: Sleep disturbances are frequent and can be exhausting.

**Work and relationships**: Due to progressive limitations, many patients stop working early. Relationships change as partners take on care responsibilities.

Outlook

MSA has a serious prognosis. Studies from recent years suggest that many patients with MSA die 6 to 10 years after diagnosis, although this varies greatly from person to person – some have a faster course, others longer.

**This says nothing about your individual course.** Prognosis studies describe averages of whole groups, not what one person will experience. Many factors play a role: which variant, how quickly symptoms develop, how well your body can handle certain complications.

Complications that can worsen the condition are:
- Severe swallowing difficulties with aspiration risk (food in airways, pneumonia)
- Breathing problems
- Heart rhythm disorders
- Severe malnutrition

Some studies suggest that good nutritional status and muscle strength may be associated with better outcomes, but this is still an area of research and says nothing about individual cases.

There is no cure for MSA. Treatment focuses on symptom management: medication for movement symptoms, blood pressure, bladder function; physiotherapy and speech therapy; home adaptations; psychological support.

Frequently asked questions

**Is MSA hereditary?**
No, in most cases MSA is not hereditary. It occurs spontaneously. There is no proven hereditary transmission from parents to children. However, research is investigating whether certain genetic variants can influence risk, but this is not the same as traditional inheritance mechanisms.

**Can MSA be prevented?**
No, there is no known way to prevent MSA. You cannot reduce the risk through a healthy lifestyle, although general health is always important for well-being.

**How quickly does MSA worsen?**
This varies greatly from person to person. Some patients notice progression over months, others over years. No test can currently predict exactly how quickly your disease will progress. This is something you will regularly evaluate in discussion with your healthcare provider.

**Can someone with MSA stay at home for a long time?**
This depends on symptoms, home situation, available support and your wishes. Many patients want to stay at home as long as possible. This usually requires help from partners, family members or professional care, and home adaptations. Your care team can help you map this out.

---

_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._

In figures

No global mortality figures

This disease is too rare to have its own place in global mortality statistics. The WHO counts it in a collection group, and no separate figure can be extracted from that.

No survival figures

Survival is systematically tracked in cancer registries. Such a registry does not exist for this disease, so there are no comparable figures on how many people are still alive five years after diagnosis.

A figure about thousands of people says nothing about one person. These figures concern all ages, health conditions and healthcare systems combined. What they mean for your situation can only be determined by your own healthcare provider.

↑ Back to top

Sources used

Above each source is a one-sentence summary of what the research is about, so you don't have to rely on an English technical title. More studies on Multiple system atrophy (MSA) can be found at publications and studies.

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.